These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32865564)

  • 1. Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions.
    Sacks CA; Van de Wiele VL; Fulchino LA; Patel L; Kesselheim AS; Sarpatwari A
    JAMA Intern Med; 2021 Jan; 181(1):16-22. PubMed ID: 32865564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of state-level pharmacist regulations on generic substitution of prescription drugs.
    Song Y; Barthold D
    Health Econ; 2018 Nov; 27(11):1717-1737. PubMed ID: 29992674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. State Laws and Generic Substitution in the Year After New Generic Competition.
    Rome BN; Sarpatwari A; Kesselheim AS
    Value Health; 2022 Oct; 25(10):1736-1742. PubMed ID: 35487821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active Surveillance of Follow-on Biologics: A Prescription for Uptake.
    Sarpatwari A; Gagne JJ; Levidow NL; Kesselheim AS
    Drug Saf; 2017 Feb; 40(2):105-108. PubMed ID: 27838823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices.
    Sarpatwari A; Lee MP; Gagne JJ; Lu Z; Dutcher SK; Jiang W; Campbell EG; Kesselheim AS
    Clin Pharmacol Ther; 2018 Jun; 103(6):1093-1099. PubMed ID: 29165800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting.
    Rathe JØ
    Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of Generic Cardiovascular Drugs in Medicare's Part D Program.
    Ma I; Tisdale RL; Vail D; Heidenreich PA; Sandhu AT
    Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e007559. PubMed ID: 34879702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of differences in state drug product selection laws on pharmacists' substitution behavior.
    Carroll NV; Fincham JE; Cox FM
    Med Care; 1987 Nov; 25(11):1069-77. PubMed ID: 3695637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. State generic substitution laws can lower drug outlays under Medicaid.
    Shrank WH; Choudhry NK; Agnew-Blais J; Federman AD; Liberman JN; Liu J; Kesselheim AS; Brookhart MA; Fischer MA
    Health Aff (Millwood); 2010 Jul; 29(7):1383-90. PubMed ID: 20606192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution.
    Mott DA; Cline RR
    Med Care; 2002 Aug; 40(8):662-74. PubMed ID: 12187180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
    Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
    JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knowledge, perceptions and practices of pharmacists regarding generic substitution in China: a cross-sectional study.
    Qu J; Zuo W; Wang S; Du L; Liu X; Gao Y; Li J; Pan H; Du X; Mei D; Took RL; Schafermeyer KW; Lukas S; Zhang B
    BMJ Open; 2021 Oct; 11(10):e051277. PubMed ID: 34663661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription drug product substitution decision support.
    Manolakis PG
    J Am Pharm Assoc (2003); 2007; 47(3):328-38. PubMed ID: 17510028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Legal and Regulatory Status of Biosimilars: How Product Naming and State Substitution Laws May Impact the United States Healthcare System.
    Paradise J
    Am J Law Med; 2015; 41(1):49-84. PubMed ID: 26237983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
    Sacks CA; Lee CC; Kesselheim AS; Avorn J
    JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perceptions and behaviors of patients and pharmacists towards generic drug substitution in Lebanon.
    Saleh S; Abou Samra C; Jleilaty S; Constantin J; El Arnaout N; Dimassi H; Al-Bittar D
    Int J Clin Pharm; 2017 Oct; 39(5):1101-1109. PubMed ID: 28823020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of U.S. federal and state generic drug policies on drug use, spending, and patient outcomes: A systematic review.
    Mishuk AU; Fasina I; Qian J
    Res Social Adm Pharm; 2020 Jun; 16(6):736-745. PubMed ID: 31445986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic substitution does not seem to affect adherence negatively in elderly polypharmacy patients.
    Olesen C; Harbig P; Barat I; Damsgaard EM
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1093-8. PubMed ID: 24038668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.